StockNews.com Initiates Coverage on Fresenius Medical Care (NYSE:FMS)

Analysts at StockNews.com assumed coverage on shares of Fresenius Medical Care (NYSE:FMS - Get Free Report) in a research note issued to investors on Saturday. The firm set a "strong-buy" rating on the stock.

FMS has been the subject of a number of other research reports. Truist Financial boosted their price objective on Fresenius Medical Care from $22.00 to $23.00 and gave the stock a "hold" rating in a report on Monday, October 7th. Berenberg Bank initiated coverage on shares of Fresenius Medical Care in a research report on Wednesday. They issued a "buy" rating and a $25.60 target price for the company. One research analyst has rated the stock with a sell rating, two have given a hold rating, two have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $24.30.

Fresenius Medical Care Stock Performance

FMS traded down $0.03 during trading hours on Friday, reaching $21.30. The company's stock had a trading volume of 229,661 shares, compared to its average volume of 301,953. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.09 and a current ratio of 1.37. The company's 50-day moving average is $20.46 and its 200-day moving average is $20.23. Fresenius Medical Care has a 52 week low of $16.86 and a 52 week high of $22.76. The firm has a market cap of $12.50 billion, a PE ratio of 17.60, a price-to-earnings-growth ratio of 1.02 and a beta of 0.91.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Wulff Hansen & CO. increased its stake in Fresenius Medical Care by 1,809.0% in the second quarter. Wulff Hansen & CO. now owns 343,429 shares of the company's stock valued at $6,556,000 after purchasing an additional 325,439 shares in the last quarter. Moran Wealth Management LLC grew its stake in shares of Fresenius Medical Care by 47.0% in the 3rd quarter. Moran Wealth Management LLC now owns 233,376 shares of the company's stock valued at $4,971,000 after buying an additional 74,621 shares during the period. Crossmark Global Holdings Inc. increased its position in Fresenius Medical Care by 60.4% in the 3rd quarter. Crossmark Global Holdings Inc. now owns 62,889 shares of the company's stock valued at $1,340,000 after buying an additional 23,692 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. bought a new stake in Fresenius Medical Care in the 3rd quarter valued at about $420,000. Finally, Triasima Portfolio Management inc. raised its stake in Fresenius Medical Care by 27.4% during the 2nd quarter. Triasima Portfolio Management inc. now owns 85,430 shares of the company's stock worth $1,631,000 after buying an additional 18,360 shares during the period. 8.25% of the stock is owned by institutional investors and hedge funds.

Fresenius Medical Care Company Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.